Silverfin false false 30/06/2025 01/07/2024 30/06/2025 J Jin 11/06/2020 16 April 2026 The principal activity of the Company in the year is that of holding investments. 12661410 2025-06-30 12661410 bus:Director1 2025-06-30 12661410 core:CurrentFinancialInstruments 2025-06-30 12661410 core:CurrentFinancialInstruments 2024-06-30 12661410 2024-06-30 12661410 core:ShareCapital 2025-06-30 12661410 core:ShareCapital 2024-06-30 12661410 core:RetainedEarningsAccumulatedLosses 2025-06-30 12661410 core:RetainedEarningsAccumulatedLosses 2024-06-30 12661410 bus:OrdinaryShareClass1 2025-06-30 12661410 2024-07-01 2025-06-30 12661410 bus:FilletedAccounts 2024-07-01 2025-06-30 12661410 bus:SmallEntities 2024-07-01 2025-06-30 12661410 bus:AuditExemptWithAccountantsReport 2024-07-01 2025-06-30 12661410 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 12661410 bus:Director1 2024-07-01 2025-06-30 12661410 2023-07-01 2024-06-30 12661410 bus:OrdinaryShareClass1 2024-07-01 2025-06-30 12661410 bus:OrdinaryShareClass1 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure xbrli:shares

Company No: 12661410 (England and Wales)

# OXFORD BIO LTD

### Unaudited Financial Statements
For the financial year ended 30 June 2025
Pages for filing with the registrar

OXFORD BIO LTD

## Unaudited Financial Statements

For the financial year ended 30 June 2025

Contents

OXFORD BIO LTD

## STATEMENT OF FINANCIAL POSITION

As at 30 June 2025
OXFORD BIO LTD

## STATEMENT OF FINANCIAL POSITION (continued)

As at 30 June 2025

| Note | 2025 |  | 2024
|  | £ |  | £
Creditors: amounts falling due within one year | 4 | ( 6,007) |  | ( 3,985)
Net current liabilities |  | (6,007) |  | (3,985)
Total assets less current liabilities |  | (6,007) |  | (3,985)
Net liabilities |  | ( 6,007) |  | ( 3,985)
Capital and reserves |  |  |  |
Called-up share capital | 5 | 100 |  | 100
Profit and loss account |  | ( 6,107 ) |  | ( 4,085 )
Total shareholders' deficit |  | ( 6,007) |  | ( 3,985)

For the financial year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Oxford Bio Ltd (registered number: 12661410) were approved and authorised for issue by the Director. They were signed on its behalf by:

J Jin Director |

16 April 2026

OXFORD BIO LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 June 2025
OXFORD BIO LTD

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 30 June 2025

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Oxford Bio Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the company's registered office is 35 Ballards Lane, London, N3 1XW, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The director has assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

##### Financial instruments

The Company only enters into basic financial instruments and transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to and from related parties and investments in non-puttable ordinary shares.

Financial assets
Basic financial assets, including trade and other debtors, and amounts due from related companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.
Such assets are subsequently carried at amortised cost using the effective interest method.
At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in the Statement of Income and Retained Earnings.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities
Basic financial liabilities, including trade and other creditors and accruals, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the company during the year, including the director | 1 |  | 1

#### 3. Fixed asset investments

Investments in shares

The Company's investments at the Statement of Financial Position date in the share capital of companies include the following:

Name of entity | Registered office | Principal activity | Class of shares | Ownership 30.06.2025 | Ownership 30.06.2024
Guangzhou Patronus Biotech Co., Ltd. | Room 601, 6F, Building 2 Standard Property Unit 3, No. 3 Luoxuan 4th Road, Guangzhou International Bio Island, Guangzhou 510005, China | Scientific research and development | Ordinary Shares | 18.75% | 18.75%

10,000,000 Ordinary Shares of 1 Chinese Yuan each acquired at £Nil consideration.

#### 4. Creditors: amounts falling due within one year

| 2025 |  | 2024
| £ |  | £
Other creditors | 6,007 |  | 3,985

#### 5. Called-up share capital

| 2025 |  | 2024
| £ |  | £
Allotted, called-up and fully-paid |  |  |
10,000 Ordinary shares of £ 0.01 each | 100 |  | 100

#### 6. Related party transactions

Transactions with the entity's director

| 2025 |  | 2024
| £ |  | £
Amounts owed to the director | (4,268) |  | (3,337)

#### 7. Ultimate controlling party

The controlling party is J Jin.